<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="anthelminthic/PMC7079787/results/search/disease/results.xml">
  <result pre="led to remarkable advances in the human–virus interaction, such as" exact="smallpox" post="eradication and the control of measles and poliomyelitis transmission."/>
  <result pre="human–virus interaction, such as smallpox eradication and the control of" exact="measles" post="and poliomyelitis transmission. Nevertheless, viruses still remain one of"/>
  <result pre="such as smallpox eradication and the control of measles and" exact="poliomyelitis" post="transmission. Nevertheless, viruses still remain one of the main"/>
  <result pre="antiviral drug to be considered successful for the treatment of" exact="herpes simplex" post="virus (HSV) and varicella zoster virus (VZV) infections. Because"/>
  <result pre="other stages of the viral cycle, causing, for example, the" exact="suppression" post="of viral gene expression [47, 48]. Fig. 1 Antiviral"/>
  <result pre="involved in human diseases, such as human immunodeficiency virus (HIV)," exact="influenza" post="H1N1, and dengue (DENV) [55–59]. One example is kalata"/>
  <result pre="assay showed that cecropin A also has inhibitory activity against" exact="herpes simplex" post="virus 1 and 2 (HSV) and against Junin virus"/>
  <result pre="was tested against HIV-1 in an assay with infected T" exact="lymphoma" post="cells. Interestingly, the cell culture treated with melittin showed"/>
  <result pre="them. In pre-incubation, in vivo assays performed with Indian vesicular" exact="stomatitis" post="virus (VSV) and MP7-NH2; the peptide made the virus"/>
  <result pre="and Hp1036, which are capable of inhibiting the replication of" exact="hepatitis" post="C virus (HCV), preventing infection installation [77]. Further assays"/>
  <result pre="swimming scorpion (Lychas mucronatus), presented outstanding inhibitory activity against the" exact="measles" post="virus, influenza H5N1, and severe acute respiratory syndrome coronavirus"/>
  <result pre="(Lychas mucronatus), presented outstanding inhibitory activity against the measles virus," exact="influenza" post="H5N1, and severe acute respiratory syndrome coronavirus (SARS-CoV). The"/>
  <result pre="outstanding inhibitory activity against the measles virus, influenza H5N1, and" exact="severe acute respiratory syndrome" post="coronavirus (SARS-CoV). The difference between mucroporin-M1 and the original"/>
  <result pre="[79]. In a further study, mucroporin-M1 showed activity against the" exact="hepatitis" post="B virus (HBV) both in vitro and in vivo,"/>
  <result pre="showed antitumor activity as well as antiviral activity against two" exact="influenza" post="variants. These peptides were also tested regarding their immunomodulatory"/>
  <result pre="an alanine-substituted magainin-2 amide along with three other peptides against" exact="vaccinia virus" post="to evaluate their virucidal activity, and the magainin-2 variant"/>
  <result pre="dermaseptins S3, S4, and S4 derivatives have been tested against" exact="rabies" post="virus in both in vitro and in vivo assays."/>
  <result pre="also affect early stages of the intracellular infection of the" exact="rabies" post="virus [93]. Moreover, HS-1, an AVP derived from anuran"/>
  <result pre="Indian frog Hydrophylax bahuvistara. Urumin showed strong inhibitory activity against" exact="influenza" post="virus in both in vitro and in vivo tests."/>
  <result pre="a TEM assay was, therefore, conducted, and this showed that" exact="influenza" post="virions were destroyed. In the in vivo assays, BALB/C"/>
  <result pre="al. [104] also showed the activity of HNP-1 against the" exact="influenza" post="A virus and suggested that this peptide inhibits the"/>
  <result pre="most initial stages of the cycle. To establish the infection," exact="influenza" post="uses the PKC signaling pathway of the cell, and"/>
  <result pre="matter. Moreover, HBD-3 also demonstrates the capability of inhibiting the" exact="vaccinia virus," post="demonstrating that the presence of the virus induces the"/>
  <result pre="demonstrates inhibitory activity toward several enveloped viruses, including: VZV; the" exact="vaccinia virus" post="(VV), HSV-1; HIV; the syncytial respiratory virus (RSV); influenza"/>
  <result pre="vaccinia virus (VV), HSV-1; HIV; the syncytial respiratory virus (RSV);" exact="influenza" post="A virus; HCV; dengue virus serotype 2; Zika virus;"/>
  <result pre="virus serotype 2; Zika virus; and, more recently, Venezuelan equine" exact="encephalitis" post="virus (VEEV), which can infect both equines and humans"/>
  <result pre="viral entry in the host cell [131]. AVPs designed from" exact="herpes simplex" post="virus Glycoprotein B is a well-conserved and important surface"/>
  <result pre="candidate for drug development [140]. Influenza virus inspired peptides The" exact="influenza" post="virus presents a major threat to human health as"/>
  <result pre="over the years [16]. Given their segmented single-stranded RNA genome," exact="influenza" post="viruses have a high degree of genomic variation, which"/>
  <result pre="triggered when an animal is infected by different strains of" exact="influenza" post="that can exchange genome segments, thus resulting in a"/>
  <result pre="In addition, the only two classes of antiviral drugs against" exact="influenza" post="are the adamantane and neuraminidase inhibitors, for which there"/>
  <result pre="157]. Based on a conserved region of the HA from" exact="influenza" post="A, several peptides were designed by López-Martinéz et al."/>
  <result pre="them were tested in vitro against four different strains of" exact="influenza" post="from human, swine and avian origin, with HA subtype"/>
  <result pre="that all nine peptides were able to inhibit the four" exact="influenza" post="strains in concentrations ranging from 20 to 74 µM."/>
  <result pre="has activity against multiple HA subtypes, and neutralized distinct human" exact="avian influenza" post="viruses such as H5N1. Furthermore, when tested in mice,"/>
  <result pre="activity against multiple HA subtypes, and neutralized distinct human avian" exact="influenza" post="viruses such as H5N1. Furthermore, when tested in mice,"/>
  <result pre="have been reported to infect humans: HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1," exact="severe acute respiratory syndrome" post="coronavirus (SARS-CoV), and the Middle East respiratory syndrome coronavirus"/>
  <result pre="2 Xenopus laevis HSV-1; HSV-2 [76] Magainin variants – HSV-1;" exact="vaccinia virus" post="[91, 92] Temporin B Rana temporaria HSV-1 [89] Dermaseptins"/>
  <result pre="Temporin B Rana temporaria HSV-1 [89] Dermaseptins Phyllomedusa HSV-1; HSV-2;" exact="rabies" post="virus; HIV-1 [22, 93–96] HS-1 H. semilineatus DENV-2 and"/>
  <result pre="HIV human immunodeficiency virus, HSV Herpes simplex virus, VSV vesicular" exact="stomatitis" post="virus, YFV yellow fever virus, RSV respiratory syncytial virus,"/>
  <result pre="virus, HSV Herpes simplex virus, VSV vesicular stomatitis virus, YFV" exact="yellow fever" post="virus, RSV respiratory syncytial virus, WNV West Nile virus,"/>
  <result pre="virus, RSV respiratory syncytial virus, WNV West Nile virus, HCV" exact="hepatitis" post="C virus, SARS-CoV severe acute respiratory syndrome coronavirus, HBV"/>
  <result pre="virus, WNV West Nile virus, HCV hepatitis C virus, SARS-CoV" exact="severe acute respiratory syndrome" post="coronavirus, HBV hepatitis B virus, DENV dengue virus, CBV-2"/>
  <result pre="hepatitis C virus, SARS-CoV severe acute respiratory syndrome coronavirus, HBV" exact="hepatitis" post="B virus, DENV dengue virus, CBV-2 coxsackievirus B2, VZV"/>
  <result pre="dengue virus, CBV-2 coxsackievirus B2, VZV varicella zoster virus, VV" exact="vaccinia virus," post="CMV cytomegalovirus Despite these molecules’ advantages, some potential problems"/>
  <result pre="type 1 protease inhibitorsArch Intern Med199715795110.1001/archinte.1997.004403000370039140265 5.KiserJJFlexnerCDirect-acting antiviral agents for" exact="hepatitis" post="C virus infectionAnnu Rev Pharmacol Toxicol20135342744910.1146/annurev-pharmtox-011112-14025423140245 6.YuFLuLDuLet al.Approaches for"/>
  <result pre="poliovirus from an immunodeficient patient with poliomyelitisJ Gen Virol2003841215122110.1099/vir.0.18974-012692287 10.ThompsonCWhitleyRNeonatal" exact="herpes simplex" post="virus infections: where are we now?Adv Exp Med Biol201169722123010.1007/978-1-4419-7185-2_1521120729"/>
  <result pre="childrenAIDS Res Hum Retroviruses20132944945510.1089/aid.2012.028323308370 15.DemingPMcNichollIRCoinfection with human immunodeficiency virus and" exact="hepatitis" post="C virus: challenges and therapeutic advances—insights from the society"/>
  <result pre="diseases pharmacistsPharmacotherapy2011435736810.1592/phco.31.4.357 16.HuiDSCLeeNChanPKSA clinical approach to the threat of emerging" exact="influenza" post="viruses in the Asia–Pacific regionRespirology2017221300131210.1111/resp.1311428677861 17.MarstonBJDokuboEKvan SteelandtAet al.Ebola response"/>
  <result pre="antiviral peptides derived from viral fusion proteins potentially active against" exact="herpes simplex" post="and influenza A virusesBioinformation2012887087410.6026/9732063000887023144542 24.ElshabrawyHAFanJHaddadCSet al.Identification of a broad-spectrum"/>
  <result pre="from viral fusion proteins potentially active against herpes simplex and" exact="influenza" post="A virusesBioinformation2012887087410.6026/9732063000887023144542 24.ElshabrawyHAFanJHaddadCSet al.Identification of a broad-spectrum antiviral small"/>
  <result pre="virusesBioinformation2012887087410.6026/9732063000887023144542 24.ElshabrawyHAFanJHaddadCSet al.Identification of a broad-spectrum antiviral small molecule against" exact="severe acute respiratory syndrome" post="coronavirus and ebola, hendra, and nipah viruses by using"/>
  <result pre="simplexAfrican J Pharm Pharmacol20093581584 26.CantatoreARandallSDTraumDAdamsSDEffect of black tea extract on" exact="herpes simplex" post="virus-1 infection of cultured cellsBMC Compl Altern Med20131311010.1186/1472-6882-13-139 27.RothanHABahraniHRahmanNAYusofRIdentification"/>
  <result pre="implications for ice bindingJ Biol Chem2013288122951230410.1074/jbc.m113.45097323486477 31.IshagHZALiCHuangLet al.Inhibition of Japanese" exact="encephalitis" post="virus infection in vitro and in vivo by pokeweed"/>
  <result pre="peptide inhibitors derived from the protein E stem against Japanese" exact="encephalitis" post="and Zika virusesAntiviral Res201714114014910.1016/j.antiviral.2017.02.00928232248 33.ChincharVGBryanLSilphadaungUet al.Inactivation of viruses infecting"/>
  <result pre="inhibits virus replicationJ Gen Virol2004852131213710.1099/vir.0.80051-015269351 38.TiwariVLiuJValyi-NagyTShuklaDAnti-heparan sulfate peptides that block" exact="herpes simplex" post="virus infection in vivoJ Biol Chem2011286254062541510.1074/jbc.m110.20110321596749 39.MooneyCHaslamNJPollastriGShieldsDCTowards the improved"/>
  <result pre="defence peptides: potential as antiviral therapeuticsBioDrugs20132747949310.1007/s40259-013-0039-023649937 46.GaldieroSFalangaATaralloRet al.Peptide inhibitors against" exact="herpes simplex" post="virus infectionsJ Pept Sci20131914815810.1002/psc.248923389903 47.QureshiAThakurNKumarMHIPdb: a database of experimentally"/>
  <result pre="Chem2010181331133610.1016/j.bmc.2009.12.026 59.SencanskiMRadosevicDPerovicVet al.Natural products as promising therapeutics for treatment of" exact="influenza" post="diseaseCurr Pharm Des2015215573558810.2174/138161282166615100211342626429712 60.HenriquesSTHuangYHRosengrenKJet al.Decoding the membrane activity of"/>
  <result pre="MatanicVCCastillaVAntiviral activity of antimicrobial cationic peptides against Junin virus and" exact="herpes simplex" post="virusInt J Antimicrob Agents20042338238910.1016/j.ijantimicag.2003.07.02215081088 73.WachingerMSaermarkTErfleVInfluence of amphipathic peptides on"/>
  <result pre="amphipathic peptides on the HIV-1 production in persistently infected T" exact="lymphoma" post="cellsFEBS Lett199230923524110.1016/0014-5793(92)80780-k1516693 74.HoodJLJalloukAPCampbellNet al.Cytolytic nanoparticles attenuate HIV-1 infectivityAntivir Ther2013189510310.3851/imp234622954649"/>
  <result pre="enveloped virusesPeptides2013489610510.1016/j.peptides.2013.07.01423891650 76.El-BitarAMSarhanMMAokiCet al.Virocidal activity of Egyptian scorpion venoms against" exact="hepatitis" post="C virus Hepatitis virusesVirol J2015121910.1186/s12985-015-0276-625591713 77.YanRZhaoZHeYet al.A new natural"/>
  <result pre="al.Inhibitory activity and mechanism of two scorpion venom peptides against" exact="herpes simplex" post="virus type 1Antiviral Res201410211010.1016/j.antiviral.2013.11.01324315793 79.LiQZhaoZZhouDet al.Virucidal activity of a"/>
  <result pre="a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and" exact="influenza" post="H5N1 virusesPeptides2011321518152510.1016/j.peptides.2011.05.01521620914 80.ZhaoZHongWZengZet al.Mucroporin-M1 inhibits hepatitis B virus replication"/>
  <result pre="against measles, SARS-CoV and influenza H5N1 virusesPeptides2011321518152510.1016/j.peptides.2011.05.01521620914 80.ZhaoZHongWZengZet al.Mucroporin-M1 inhibits" exact="hepatitis" post="B virus replication by activating the mitogen-activated protein kinase"/>
  <result pre="86.MarcocciMEAmatoreDVillaSet al.The amphibian antimicrobial peptide temporin b inhibits in vitro" exact="herpes simplex" post="virus 1 infectionAntimicrob Agents Chemother20186211310.1128/aac.02367-17 87.ShartounyJRJacobJMining the tree of"/>
  <result pre="Dev Biol20188814715510.1016/j.semcdb.2018.03.00129524585 88.EgalMConradMMacDonaldDLet al.Antiviral effects of synthetic membrane-active peptides on" exact="herpes simplex" post="virus, type 1Int J Antimicrob Agents199913576010.1016/S0924-8579(99)00094-110563406 89.DeanREO’BrienLMThwaiteJEet al.A carpet-based"/>
  <result pre="89.DeanREO’BrienLMThwaiteJEet al.A carpet-based mechanism for direct antimicrobial peptide activity against" exact="vaccinia virus" post="membranesPeptides2010311966197210.1016/j.peptides.2010.07.02820705109 90.BelaidAAouniMKhelifaRet al.In vitro antiviral activity of dermaseptins against"/>
  <result pre="virus membranesPeptides2010311966197210.1016/j.peptides.2010.07.02820705109 90.BelaidAAouniMKhelifaRet al.In vitro antiviral activity of dermaseptins against" exact="herpes simplex" post="virus type 1J Med Virol20026622923410.1002/jmv.213411782932 91.LorinCSaidiHBelaidAet al.The antimicrobial peptide"/>
  <result pre="activity of dermaseptin S4 and derivatives from amphibian skin against" exact="herpes simplex" post="virus type 2J Med Virol20138527228110.1002/jmv.2345023161023 93.MechliaMBBelaidACastelGet al.Dermaseptins as potential"/>
  <result pre="amphibian host defense peptide is virucidal for human H1 hemagglutinin-bearing" exact="influenza" post="virusesImmunity20174658759510.1016/j.immuni.2017.03.01828423338 96.YasinBPangMTurnerJSet al.Evaluation of the inactivation of infectious herpes"/>
  <result pre="hemagglutinin-bearing influenza virusesImmunity20174658759510.1016/j.immuni.2017.03.01828423338 96.YasinBPangMTurnerJSet al.Evaluation of the inactivation of infectious" exact="herpes simplex" post="virus by host-defense peptidesEur J Clin Microbiol Infect Dis20001918719410.1007/s10096005045710795591"/>
  <result pre="Dis20001918719410.1007/s10096005045710795591 97.Carriel-GomesMCKratzJMBarraccoMAet al.In vitro antiviral activity of antimicrobial peptides against" exact="herpes simplex" post="virus 1, adenovirus, and rotavirusMem Inst Oswaldo Cruz200710246947210.1590/s0074-0276200700500002817612767 98.LuZVan"/>
  <result pre="One20127e4704710.1371/journal.pone.004704723056574 100.Vilas BoasLCPde LimaLMPMiglioloLet al.Linear antimicrobial peptides with activity against" exact="herpes simplex" post="virus 1 and Aichi virusBiopolymers201710812010.1002/bip.22871 101.HollyMKDiazKSmithJGDefensins in Viral Infection"/>
  <result pre="4 inhibits HIV-1 infection in vitroFEBS Lett200557916216610.1016/j.febslet.2004.11.06215620707 104.SalvatoreMGarcía-SastreARuchalaPet al.α-defensin inhibits" exact="influenza" post="virus replication by cell-mediated mechanism(s)J Infect Dis200719683584310.1086/52102717703413 105.Meyer-HoffertUSchwarzTSchröderJ-MGläserRExpression of"/>
  <result pre="proteinase 3Blood2001973951395910.1182/blood.v97.12.395111389039 109.BarlowPGSvobodaPMackellarAet al.Antiviral activity and increased host defense against" exact="influenza" post="infection elicited by the human cathelicidin LL-37PLoS One201161910.1371/journal.pone.0025333 110.TripathiSWangGWhiteMet"/>
  <result pre="human cathelicidin, LL-37, and derived peptides on seasonal and pandemic" exact="influenza" post="A virusesPLoS One20151011710.1371/journal.pone.0124706 111.MatsumuraTSugiyamaNMurayamaAet al.Antimicrobial peptide LL-37 attenuates infection"/>
  <result pre="A virusesPLoS One20151011710.1371/journal.pone.0124706 111.MatsumuraTSugiyamaNMurayamaAet al.Antimicrobial peptide LL-37 attenuates infection of" exact="hepatitis" post="C virusHepatol Res20164692493210.1111/hepr.1262726606891 112.AlagarasuKPatilPSShilPet al.In-vitro effect of human cathelicidin"/>
  <result pre="cathelicidin peptide LL-37 as a therapeutic antiviral targeting Venezuelan equine" exact="encephalitis" post="virus infectionsAntiviral Res2019164616910.1016/j.antiviral.2019.02.00230738837 114.HeMZhangHLiYet al.Cathelicidin-derived antimicrobial peptides inhibit Zika"/>
  <result pre="trafficking of Herpes simplex virus-1Biochimie20099116016410.1016/j.biochi.2008.05.01618573311 124.ShestakovAJenssenHNordströmIErikssonKLactoferricin but not lactoferrin inhibit" exact="herpes simplex" post="virus type 2 infection in miceAntiviral Res20129334034510.1016/j.antiviral.2012.01.00322269645 125.WangWYWongJHIpDTMet al.Bovine"/>
  <result pre="antiviral peptidesComput Biol Med201910712713010.1016/j.compbiomed.2019.02.01130802694 130.JoseGGLarsenIVGaugerJet al.A cationic peptide, TAT-Cd0, inhibits" exact="herpes simplex" post="virus type 1 ocular infection in vivoInvestig Ophthalmol Vis"/>
  <result pre="inhibitory peptidesPLoS Negl Trop Dis20104e72110.1371/journal.pntd.000072120582308 136.RoizmanBTaddeoBet al.ArvinACampadelli-FiumeGMocarskiEet al.The strategy of" exact="herpes simplex" post="virus replication and takeover of the host cellHuman herpesviruses:"/>
  <result pre="therapy, and immunoprophylaxis2007CambridgeCambridge University Press 137.AkkarawongsaRPocaroNECaseGet al.Multiple peptides homologous to" exact="herpes simplex" post="virus type 1 glycoprotein B inhibit viral infectionAntimicrob Agents"/>
  <result pre="Chemother20095398799610.1128/aac.00793-0819104014 138.Cetina-CoronaALópez-SánchezUSalinas-TrujanoJet al.Peptides derived from glycoproteins H and B of" exact="herpes simplex" post="virus type 1 and herpes simplex virus type 2"/>
  <result pre="H and B of herpes simplex virus type 1 and" exact="herpes simplex" post="virus type 2 are capable of blocking herpetic infection"/>
  <result pre="HIV-2, and Simian immunodeficiencyVirus20179111510.1128/jvi.01839-16 153.HsiehIHartshornKLThe role of antimicrobial peptides in" exact="influenza" post="virus infection and their potential as antiviral and immunomodulatory"/>
  <result pre="A (H1N1) Virus Investigation TeamDawoodFSJainSet al.Emergence of a novel swine-origin" exact="influenza" post="A (H1N1) virus in humansN Engl J Med20093602605261510.1056/nejmoa090381019423869 155.KoszalkaPTilmanisDHurtACInfluenza"/>
  <result pre="trialInfluenza Other Respi Viruses20171124024610.1111/irv.12446 156.VanderlindenENaesensLEmerging antiviral strategies to interfere with" exact="influenza" post="virus entryMed Res Rev20143430133910.1002/med.2128923801557 157.LinDLuoYYangGet al.Potent influenza A virus"/>
  <result pre="to interfere with influenza virus entryMed Res Rev20143430133910.1002/med.2128923801557 157.LinDLuoYYangGet al.Potent" exact="influenza" post="A virus entry inhibitors targeting a conserved region of"/>
  <result pre="inhibitors targeting a conserved region of hemagglutininBiochem Pharmacol2017144355110.1016/j.bcp.2017.07.02328774731 158.López-MartínezRRamírez-SalinasGLCorrea-BasurtoJBarrónBLInhibition of" exact="influenza" post="A virus infection in vitro by peptides designed in"/>
  <result pre="computationally designed hemagglutinin stem-binding protein provides in vivo protection from" exact="influenza" post="independent of a host immune responsePLoS Pathogens201612e100540910.1371/journal.ppat.100540926845438 160.FriedmanNAlterHHindiyehMet al.Human"/>
 </snippets>
</snippetsTree>
